Skip to content

Study · In vitro (cells) · 2012

3 results

[Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)].

Dzhokhadze TA, Buadze TZh, Gaĭozishvili MN, Baratashvili NA, Lezhava TA

Georgian medical news1 Nov 2012

PMID23221144 (opens in a new tab)PepBankPUB-23221144
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In lab tests, Prostamax increased sister chromatid exchange frequency compared with intact cells.

    In plain wordsIn lab tests, Prostamax increased sister chromatid exchanges compared with intact cells.

    Peptide
    Prostamax (KEDP)
    Outcome
    IncreaseSister chromatid exchange frequency
    Study

    humann: not reported in source

    cells from old individuals
    Comparator
    Intact cells
    Outcome group
    Aging markers · Aging and longevity
    Studied dose
    Dose not stated

    Measurements

    SCE frequency
    12 exchange per cell
    Prostamax; reported uncertainty ±0.28, type not stated
    SCE frequency
    5.9 exchange per cell
    intact cells; reported uncertainty ±0.2, type not stated

    Source sentences

    Summary
    Prostamax changed the chromosomal parameters: 1) increased the frequency of SCE to 12,0±0,28 exchange in per cell (in intact cells - 5,9±0,2);
    1 context sentence
    Summary · context
    In this work is presented the data on the variability of the functional characteristics of the chromosomes in the cells exposed by oligopeptide bioregulator - Prostamax from old individuals (75-86 years).
  2. 02LabIn vitro (cells)Mechanism

    In lab tests, Prostamax increased Ag-positive NOR frequency compared with intact cells.

    In plain wordsIn lab tests, Prostamax increased Ag-positive NOR frequency compared with intact cells.

    Peptide
    Prostamax (KEDP)
    Outcome
    IncreaseAg-positive NOR frequency
    Study

    humann: not reported in source

    cells from old individuals
    Comparator
    Intact cells
    Outcome group
    Aging markers · Aging and longevity
    Studied dose
    Dose not stated

    Measurements

    Ag-positive NOR frequency
    2.5 per cell
    Prostamax
    Ag-positive NOR frequency
    0.95 per cell
    intact cells

    Source sentences

    Summary
    2) increased the frequency of Ag-positive NORs to 2.5 per cell (in intact cells - 0.95)
    1 context sentence
    Summary · context
    In this work is presented the data on the variability of the functional characteristics of the chromosomes in the cells exposed by oligopeptide bioregulator - Prostamax from old individuals (75-86 years).
  3. 03LabIn vitro (cells)Mechanism

    In lab tests, Prostamax reduced large pericentromeric heterochromatin segment frequency in the 1st and 9th chromosomes.

    In plain wordsIn lab tests, Prostamax reduced large heterochromatin segment frequency in the 1st and 9th chromosomes.

    Peptide
    Prostamax (KEDP)
    Outcome
    DecreaseLarge pericentromeric heterochromatin segments
    Study

    humann: not reported in source

    cells from old individuals
    Outcome group
    Aging markers · Aging and longevity
    Studied dose
    Dose not stated

    Source sentences

    Summary
    3) reduced in the frequency of large segments of the options from the pericentromeric heterochromatin for the 1st and 9th chromosomes.
    1 context sentence
    Summary · context
    In this work is presented the data on the variability of the functional characteristics of the chromosomes in the cells exposed by oligopeptide bioregulator - Prostamax from old individuals (75-86 years).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.